JNJ-5120/PIPE-307 - (MOONLIGHT-1)

September 14, 2026: Contineum Therapeutics (NASDAQ: CTNM) announced that the Phase 2 MOONLIGHT-1 trial of JNJ-5120/PIPE-307 in adult patients with major depressive disorder did not meet its primary efficacy endpoint, which was improvement from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Day 5 versus placebo. The randomized, double-blind, multicenter, placebo-controlled proof-of-concept study evaluated JNJ-5120/PIPE-307 as monotherapy.

The company said JNJ-5120/PIPE-307 was well tolerated and showed no new safety signals. Analyses of the data, including prespecified exploratory endpoints, are ongoing.

JNJ-5120/PIPE-307 is being developed by Johnson & Johnson under a global license and development agreement. Johnson & Johnson is continuing to review the full dataset, including exploratory endpoint results, to assess the totality and clinical relevance of the findings and determine next steps. The trial is listed as NCT06785012.